4 Weeks Treatment of Type II Diabetic Patients With BI 44847
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the current study is to investigate the safety and tolerability of
BI 44847 in male and female patients with type 2 diabetes following oral administration of
repeated doses of 100 mg b.i.d, 400 mg b.i.d. and 800 mg b.i.d. over 28 days.
A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI
44847 after multiple dosing, including assessment of steady state.